Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04318938
Recruitment Status : Recruiting
First Posted : March 24, 2020
Last Update Posted : November 12, 2020
Sponsor:
Information provided by (Responsible Party):
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest